Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET-CT for Prostate Cancer Staging
NCT03852654Phase 3Unknown
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of piflufolastat f 18 in prostate cancer (PCa). Primary endpoint: Percent of Veterans with M1 disease identified by 18F-DCFPyL PET-CT at 120 days. Status: unknown.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03852654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852654.